User: Guest

  



DOMAIN EXPERT ENGAGEMENTS

Number of executives repeatedly engaged by snail & email outreach*

POOL + OUTREACH

Interactions with Platform & by Email *

INTERACTIONS

Unique # Participated *

PARTICIPANTS

Responses Validated *

VALIDATIONS

* Platform engagements are dynamic. Stats are published quarterly.


  •  CODE

  •  PAGES

  •  DATE

  •  PRICE

    $

  •  DATA EXHIBITS

    125


TABLE OF CONTENTS


   Pages :    | $

   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
  
   Product Definitions and Scope of Study.....I-3  
   Market Scenario.....II-1
Current & Future Analysis.....II-1
Challenges.....II-1
1$120
   Opportunity for Novel Therapies.....II-2
Competitive Scenario.....II-2
Major Drugs.....II-2
Viagra (sildenafil).....II-2
Cialis (tadalafil).....II-2
1$120
   Levitra (vardenafil hydrochloride).....II-3
Comparative Analysis.....II-3
Similarities.....II-3
Differences.....II-3
Side Effects.....II-3
1$120
   Introduction.....II-4
Erectile Dysfunction.....II-4
Pathophysiology.....II-4
1$120
   Causes.....II-5
Symptoms.....II-5
Diagnosis.....II-5
Medical Diagnosis.....II-5
1$120
   Patient History.....II-6
Physical Examination.....II-6
Laboratory Tests.....II-6
Other Tests.....II-6
1$120
   Psychosocial Examination.....II-7
Clinical Tests.....II-7
Duplex Ultrasound.....II-7
Bulbocavernosus Reflex Test.....II-7
Nocturnal Penile Tumescence.....II-7
Penile Biothesiometry.....II-7
Penile Angiogram.....II-7
1$120
   Corpus Cavernosometry.....II-8
Digital Subtraction Angiography (DSA).....II-8
Magnetic Resonance Angiography.....II-8
Treatment.....II-8
Overview.....II-8
1$120
   Psychotherapy.....II-9
Behavioral Changes.....II-9
Stop Smoking.....II-9
Control Cholesterol.....II-9
Reduction in Fat.....II-9
Oral Treatment.....II-9
1$120
   Drug Therapy.....II-10
Other Non-Invasive Treatments.....II-10
Vacuum Constriction Device.....II-10
1$120
   Minimal Invasive Therapies.....II-11
Surgery.....II-11
Penile Prostheses.....II-11
Arterial Surgery.....II-11
1$120
   Venous Surgery.....II-12
Latest Advancements in Treatments.....II-12
Future Medications for Treatment of Erectile Dysfunction.....II-12
Alprostadil.....II-12
Apomorphine.....II-12
Meloncortin Stimulators.....II-12
1$120
   Gene Therapy.....II-13
Unapproved and Controversial Treatments.....II-13
Naltrexone.....II-13
Bremelanotide.....II-13
Melanotan II.....II-13
hMaxi-K.....II-13
Enzyte.....II-13
Prelox.....II-13
1$120
   Yohimbe.....II-14
Natural Remedies.....II-14
L-Arginine.....II-14
Ginkgo.....II-14
Ginseng.....II-14
1$120
   Ashwagandha.....II-15
Cordiceps Sinensis.....II-15
Horny Goat Weed.....II-15
Chinese Angelica.....II-15
Pomegranate Juice.....II-15
1$120
   Warner Chilcott Inks Agreement with Dong-A PharmTech.....II-16
Warner Chilcott Signs Agreement with NexMed.....II-16
Coloplast Establishes US Headquarters.....II-16
Vivus Commences Phase-III Trials of Avanafil.....II-16
1$120
   Skreem Entertainment Inks Letter of Intent to Purchase EdMed.....II-17
Eli Lilly Receives FDA Approval for Cialis®.....II-17
Eli Lilly Partners with Sanofi-Aventis.....II-17
Deerfield Management Collaborates with Vivus.....II-17
Eli Lilly Purchases ICOS.....II-17
1$120
   Abbott Laboratories (US).....II-18
Eli Lilly and Company, Inc. (US).....II-18
F. Hoffmann-La Roche, Inc. (US).....II-18
GlaxoSmithKline plc (UK).....II-18
1$120
   Nexmed, Inc. (US).....II-19
Pfizer, Inc. (US).....II-19
Sanofi-aventis SA (France).....II-19
Vivus, Inc. (US).....II-19
Warner Chilcott Limited (US).....II-19
1$120
   Table 1: World Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Geographic Region - US, Canada, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....II-201$350
   Table 2: World Historic Review for Erectile Dysfunction Drugs by Geographic Region - US, Canada, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).....II-211$350
   Table 3: World 13-Year Perspective for Erectile Dysfunction Drugs by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, and Rest of World Markets for Years 2003, 2009 & 2015 (includes corresponding Graph/Chart).....II-221$350
   A. Market Analysis.....III-1
Current & Future Analysis.....III-1
ED Market Witnesses Robust Demand.....III-1
User Base Expands with Better Understanding of Disease Indications.....III-1
Lower Market Penetration Offers Growth Opportunities.....III-1
1$100
   Lack of Insurance Coverage Affects ED Drug Sales.....III-2
Strategic Corporate Developments.....III-2
2$125
   Select Players.....III-4
Abbott Laboratories.....III-4
Eli Lilly and Company, Inc......III-4
F. Hoffmann-La Roche, Inc......III-4
Nexmed, Inc......III-4
1$100
   Pfizer, Inc......III-5
Vivus, Inc......III-5
Warner Chilcott Limited.....III-5
1$100
   B. Market Analytics.....III-6
Table 4: US Recent Past, Current and Future Analysis for Erectile Dysfunction Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....III-6

Table 5: US Historic Review for Erectile Dysfunction Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).....III-6
1$200
   Market Analysis.....III-7
Table 6: Canadian Recent Past, Current and Future Analysis for Erectile Dysfunction Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....III-7
1$200
   Table 7: Canadian Historic Review for Erectile Dysfunction Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).....III-81$200
   Market Analysis.....III-9
Table 8: Japanese Recent Past, Current and Future Analysis for Erectile Dysfunction Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....III-9
1$200
   Table 9: Japanese Historic Review for Erectile Dysfunction Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).....III-101$200
   A. Market Analysis.....III-11
Current & Future Analysis.....III-11
Market for Erectile Dysfunction Products to Rise.....III-11
Development of Novel Drugs for ED and Lifestyle Disorders.....III-11
1$100
   B. Market Analytics.....III-12
Table 10: European Recent Past, Current and Future Analysis for Erectile Dysfunction Drugs by Geographic Region - France, Germany, Italy, UK, and Rest of Europe Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....III-12
1$200
   Table 11: European Historic Review for Erectile Dysfunction Drugs by Geographic Region - France, Germany, Italy, UK, and Rest of Europe Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).....III-131$200
   Table 12: European 13-Year Perspective for Erectile Dysfunction Drugs by Country/Region - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, and Rest of Europe Markets for Years 2003, 2009 and 2015 (includes corresponding Graph/Chart).....III-141$200
   A. Market Analysis.....III-15
Current & Future Analysis.....III-15
Sanofi-Aventis SA – A Major French Player.....III-15
1$100
   B. Market Analytics.....III-16
Table 13: French Recent Past, Current and Future Analysis for Erectile Dysfunction Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....III-16
1$200
   Table 14: French Historic Review for Erectile Dysfunction Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).....III-171$200
   Market Analysis.....III-18
Table 15: German Recent Past, Current and Future Analysis for Erectile Dysfunction Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....III-18
1$200
   Table 16: German Historic Review for Erectile Dysfunction Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).....III-191$200
   Market Analysis.....III-20
Table 17: Italian Recent Past, Current and Future Analysis for Erectile Dysfunction Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....III-20
1$200
   Table 18: Italian Historic Review for Erectile Dysfunction Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).....III-211$200
   A. Market Analysis.....III-22
Current & Future Analysis.....III-22
GlaxoSmithKline plc – A Major UK Player.....III-22
1$100
   B. Market Analytics.....III-23
Table 19: UK Recent Past, Current and Future Analysis for Erectile Dysfunction Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....III-23
1$200
   Table 20: UK Historic Review for Erectile Dysfunction Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).....III-241$200
   A. Market Analysis.....III-25
Current & Future Analysis.....III-25
Strategic Corporate Development.....III-25
1$100
   B. Market Analytics.....III-26
Table 21: Rest of Europe Recent Past, Current and Future Analysis for Erectile Dysfunction Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....III-26
1$200
   Table 22: Rest of Europe Historic Review for Erectile Dysfunction Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).....III-271$200
   Market Analysis.....III-28
Table 23: Rest of World Recent Past, Current and Future Analysis for Erectile Dysfunction Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....III-28
1$200
   Table 24: Rest of World Historic Review for Erectile Dysfunction Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).....III-291$200
    
 
 


Sales queries: Sales@StrategyR.com
Research queries: Info411@StrategyR.com